Thyroid Gland Disorder Treatment Market by Disease Type, Drug Type, Route of Administration, and Distribution/Sales Channel - Global Opportunity Analysis and Industry Forecast, 2017-2025

  • ID: 4603670
  • Report
  • Region: Global
  • 243 pages
  • Allied Analytics LLP
1 of 4
Thyroid Gland Disorder Treatment Market by Disease Type (Hyperthyroidism and Hypothyroidism), Drug Type (Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based Compound, and Others), Route of Administration (Oral, Intravenous, and Others), and Distribution/Sales Channel (Wholesaler/Distributor, Retailer, Mail-order Pharmacy, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2025

The global thyroid gland disorder market was valued at $2,057 million in 2017, and is estimated to reach $2,771 million at a CAGR of 3.8% from 2018 to 2025. Thyroid gland disorder treatments are indicated for thyroid disorders that occur in the thyroid gland of a human body. Thyroid disorder is defined as an abnormal release of thyroid hormones that play a key role in the regulation of metabolism. The thyroid disease occurs mainly due to a deficiency of iodine in the body.

Rise in the incidence of thyroid gland disorder, increase in the number of disease awareness programs especially in the developing countries, and development of effective combination drug therapies to treat thyroid gland disorder majorly drive the growth of the global thyroid gland disorder treatment market. However, side effects of the drugs leading to low adherence and stringent government regulations for the approval of combination of therapies hamper the market growth. Presence of large pool of undiagnosed patients due to asymptomatic nature of thyroid disorders help to open new avenues for the growth of the thyroid gland disorder treatment market in the near future.

The global thyroid gland disorder treatment market is segmented based on disease type, drug type, route of administration, distribution channel, and region. Based on disease type, the market is bifurcated into hypothyroidism and hyperthyroidism. Based on drug type, the market is categorized into levothyroxine, liothyronine, propylthiouracil, imidazole-based compounds, and others. Based on route of administration, the market is classified into oral, intravenous, and others. Based on distribution channel, the market is categorized into wholesaler or distributor, retailer, mail-order pharmacy, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS:

This report entails a detailed quantitative analysis of the current market trends from 2017 to 2025 to identify the prevailing opportunities.
Market estimations are based on comprehensive analysis of the key developments in the industry.
The global market is comprehensively analyzed with respect to disease type, drug type, route of administration, distribution channels, and region.
In-depth analysis based on region assists to understand the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS:

By Disease Type

Hypothyroidism
Hyperthyroidism

By Drug Type

Levothyroxine
Liothyronine
Propylthiouracil
Imidazole-based Compound
Others

By Route of Administration

Oral
Intravenous
Others

By Distribution Channel

Wholesaler/Distributor
Retailer
Mail-order Pharmacy
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Others
Asia-Pacific
Japan
China
Australia
India
South Korea
Others
LAMEA
Brazil
Saudi Arabia
South Africa
Others

KEY PLAYERS PROFILED:

AbbVie Inc.
Pfizer Inc.
Merck & Co., Inc.
Lannett Company, Inc.
Allergan plc
Mylan N.V.
GlaxoSmithKline plc
Novartis AG
RLC LABS, Inc.
Abbott Laboratories

The other players of the thyroid gland disorder treatment market include (companies not profiled in the report):

Takeda Pharmaceutical Company Limited
Aspen
Amgen Inc.
Endo International plc
Acella Pharmaceuticals, LLC
Gemini Laboratories, LLC.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report

CHAPTER 2: EXECUTIVE SUMMARY
2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Market share analysis, 2017
3.4. Porters five forces analysis
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in incidence of thyroid gland disorders
3.5.1.2. Development of effective combination thyroid disorders drug therapies
3.5.1.3. Increase in number of disease awareness programs in developing regions
3.5.2. Restraints
3.5.2.1. Side effects that cause lesser patient adherence
3.5.2.2. Stringent government regulations
3.5.3. Opportunities
3.5.3.1. Availability of large pool of undiagnosed patients due to asymptomatic nature of thyroid disorders

CHAPTER 4: THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Hypothyroidism
4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Hyperthyroidism
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country

CHAPTER 5: THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Levothyroxine
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Liothyronine
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Propylthiouracil
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Imidazole-based compounds
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Others
5.6.1. Market size and forecast
5.6.2. Market analysis, by country

CHAPTER 6: THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Oral route
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Intravenous route
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Others
6.4.1. Market size and forecast
6.4.2. Market analysis, by country

CHAPTER 7: THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Wholesalers/Distributors
7.2.1. Market size and forecast
7.2.2. Market analysis, by country
7.3. Retailer
7.3.1. Market size and forecast
7.3.2. Market analysis, by country
7.4. Mail-Order Pharmacy
7.4.1. Market size and forecast
7.4.2. Market analysis, by country
7.5. Others
7.5.1. Market size and forecast
7.5.2. Market analysis, by country

CHAPTER 8: THYROID GLAND DISORDER TREATMENT MARKET, BY GEOGRAPHY
8.1. OVERVIEW
8.1.1. Market size and forecast
8.2. NORTH AMERICA
8.2.1. Key market trends and opportunities
8.2.2. North America thyroid gland disorder treatment market by disease type
8.2.3. North America thyroid gland disorder treatment market by drug type
8.2.4. North America thyroid gland disorder treatment market by route of administration
8.2.5. North America thyroid gland disorder treatment market by distribution channel
8.2.6. Market size and forecast, by country
8.2.6.1. U.S. thyroid gland disorder treatment market by disease type
8.2.6.2. U.S. thyroid gland disorder treatment market by drug type
8.2.6.3. U.S. thyroid gland disorder treatment market by route of administration
8.2.6.4. U.S. thyroid gland disorder treatment market by distribution channel
8.2.6.5. Canada thyroid gland disorder treatment market by disease type
8.2.6.6. Canada thyroid gland disorder treatment market by drug type
8.2.6.7. Canada thyroid gland disorder treatment market by route of administration
8.2.6.8. Canada thyroid gland disorder treatment market by distribution channel
8.2.6.9. Mexico thyroid gland disorder treatment market by disease type
8.2.6.10. Mexico thyroid gland disorder treatment market by drug type
8.2.6.11. Mexico thyroid gland disorder treatment market by route of administration
8.2.6.12. Mexico thyroid gland disorder treatment market by distribution channel
8.3. EUROPE
8.3.1. Key market trends and opportunities
8.3.2. Europe thyroid gland disorder treatment market by disease type
8.3.3. Europe thyroid gland disorder treatment market by drug type
8.3.4. Europe thyroid gland disorder treatment market by route of administration
8.3.5. Europe thyroid gland disorder treatment market by distribution channel
8.3.6. Market size and forecast, by country
8.3.6.1. Germany thyroid gland disorder treatment market by disease type
8.3.6.2. Germany thyroid gland disorder treatment market by drug type
8.3.6.3. Germany thyroid gland disorder treatment market by route of administration
8.3.6.4. Germany thyroid gland disorder treatment market by distribution channel
8.3.6.5. France thyroid gland disorder treatment market by disease type
8.3.6.6. France thyroid gland disorder treatment market by drug type
8.3.6.7. France thyroid gland disorder treatment market by route of administration
8.3.6.8. France thyroid gland disorder treatment market by distribution channel
8.3.6.9. UK thyroid gland disorder treatment market by disease type
8.3.6.10. UK thyroid gland disorder treatment market by drug type
8.3.6.11. UK thyroid gland disorder treatment market by route of administration
8.3.6.12. UK thyroid gland disorder treatment market by distribution channel
8.3.6.13. Italy thyroid gland disorder treatment market by disease type
8.3.6.14. Italy thyroid gland disorder treatment market by drug type
8.3.6.15. Italy thyroid gland disorder treatment market by route of administration
8.3.6.16. Italy thyroid gland disorder treatment market by distribution channel
8.3.6.17. Spain thyroid gland disorder treatment market by disease type
8.3.6.18. Spain thyroid gland disorder treatment market by drug type
8.3.6.19. Spain thyroid gland disorder treatment market by route of administration
8.3.6.20. Spain thyroid gland disorder treatment market by distribution channel
8.3.6.21. Rest of Europe thyroid gland disorder treatment market by disease type
8.3.6.22. Rest of Europe thyroid gland disorder treatment market by drug type
8.3.6.23. Rest of Europe thyroid gland disorder treatment market by route of administration
8.3.6.24. Rest of Europe thyroid gland disorder treatment market by distribution channel
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Asia-Pacific thyroid gland disorder treatment market by disease type
8.4.3. Asia-Pacific thyroid gland disorder treatment market by drug type
8.4.4. Asia-Pacific thyroid gland disorder treatment market by route of administration
8.4.5. Asia-Pacific thyroid gland disorder treatment market by distribution channel
8.4.6. Market size and forecast, by country
8.4.6.1. Japan thyroid gland disorder treatment market by disease type
8.4.6.2. Japan thyroid gland disorder treatment market by drug type
8.4.6.3. Japan thyroid gland disorder treatment market by route of administration
8.4.6.4. Japan thyroid gland disorder treatment market by distribution channel
8.4.6.5. China thyroid gland disorder treatment market by disease type
8.4.6.6. China thyroid gland disorder treatment market by drug type
8.4.6.7. China thyroid gland disorder treatment market by route of administration
8.4.6.8. China thyroid gland disorder treatment market by distribution channel
8.4.6.9. Australia thyroid gland disorder treatment market by disease type
8.4.6.10. Australia thyroid gland disorder treatment market by drug type
8.4.6.11. Australia thyroid gland disorder treatment market by route of administration
8.4.6.12. Australia thyroid gland disorder treatment market by distribution channel
8.4.6.13. India thyroid gland disorder treatment market by disease type
8.4.6.14. India thyroid gland disorder treatment market by drug type
8.4.6.15. India thyroid gland disorder treatment market by route of administration
8.4.6.16. India thyroid gland disorder treatment market by distribution channel
8.4.6.17. South Korea thyroid gland disorder treatment market by disease type
8.4.6.18. South Korea thyroid gland disorder treatment market by drug type
8.4.6.19. South Korea thyroid gland disorder treatment market by route of administration
8.4.6.20. South Korea thyroid gland disorder treatment market by distribution channel
8.4.6.21. Rest of Asia-Pacific thyroid gland disorder treatment market by disease type
8.4.6.22. Rest of Asia-Pacific thyroid gland disorder treatment market by drug type
8.4.6.23. Rest of Asia-Pacific thyroid gland disorder treatment market by route of administration
8.4.6.24. Rest of Asia-Pacific thyroid gland disorder treatment market by distribution channel
8.5. LAMEA
8.5.1. Key market trends and opportunities
8.5.2. LAMEA thyroid gland disorder treatment market by disease type
8.5.3. LAMEA thyroid gland disorder treatment market by drug type
8.5.4. LAMEA thyroid gland disorder treatment market by route of administration
8.5.5. LAMEA thyroid gland disorder treatment market by distribution channel
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil thyroid gland disorder treatment market by disease type
8.5.6.2. Brazil thyroid gland disorder treatment market by drug type
8.5.6.3. Brazil thyroid gland disorder treatment market by route of administration
8.5.6.4. Brazil thyroid gland disorder treatment market by distribution channel
8.5.6.5. Saudi Arabia thyroid gland disorder treatment market by disease type
8.5.6.6. Saudi Arabia thyroid gland disorder treatment market by drug type
8.5.6.7. Saudi Arabia thyroid gland disorder treatment market by route of administration
8.5.6.8. Saudi Arabia thyroid gland disorder treatment market by distribution channel
8.5.6.9. South Africa thyroid gland disorder treatment market by disease type
8.5.6.10. South Africa thyroid gland disorder treatment market by drug type
8.5.6.11. South Africa thyroid gland disorder treatment market by route of administration
8.5.6.12. South Africa thyroid gland disorder treatment market by distribution channel
8.5.6.13. Rest of LAMEA thyroid gland disorder treatment market by disease type
8.5.6.14. Rest of LAMEA thyroid gland disorder treatment market by drug type
8.5.6.15. Rest of LAMEA thyroid gland disorder treatment market by route of administration
8.5.6.16. Rest of LAMEA thyroid gland disorder treatment market by distribution channel

CHAPTER 9: COMPANY PROFILES
9.1. Abbott Laboratories
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.2. AbbVie Inc.
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segment
9.2.4. Product portfolio
9.2.5. Business performance
9.3. Allergan Plc.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.4. GlaxoSmithKline plc
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.5. Lannett Company, Inc.
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.6. Merck & Co. Inc.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance
9.7. Mylan N.V.
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.8. Novartis AG
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.9. Pfizer Inc.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.10. RLC LABS, Inc.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, Thyroid Gland Disorder Treatment Market by Drug Type, Route of Administration, Distribution/Sales Channel, and Disease Type: Global Opportunity Analysis and Industry Forecast, 20172025," the global thyroid gland disorder market was valued at $2,057 million in 2017, and is estimated to reach $2,771 million at a CAGR of 3.8% from 2018 to 2025. North America was the highest contributor to the thyroid gland disorder treatment market in 2017; however, Asia-Pacific is expected to witness the highest growth during the forecast period.

The thyroid gland produces hormones, which regulates the body metabolism. The abnormal release of thyroid hormones causes thyroid disorder. Thyroid hormone is necessary to regulate the heart rate, blood pressure, and body temperature. However, due to factors such as iodine deficiency, autoimmunity, and congenital hypothyroidism, one-third of the population is at the risk of having thyroid disease.

The major factors that drive the growth of the thyroid gland disorder market include increase in incidence of thyroid gland disorders, development of effective combination thyroid disorders drug therapies, and increase in number of disease awareness programs in developing regions. However, side effects of the medication and stringent government regulations limit the market growth. Conversely, availability of large pool of undiagnosed patients due to asymptomatic nature of thyroid disorders in the emerging economies are anticipated to provide numerous opportunities for the market growth during the forecast period.

Among the disease type, the hypothyroidism segment occupied the largest share, and is anticipated to continue its dominance during the forecast period, owing to the high prevalence of iodine deficiency population worldwide, and is the most commonly occurring thyroid disorder.

Among the distribution channel, the wholesaler or distributor segment occupied the largest share. However, mail-order pharmacy is the fastest growing segment as these services help customers save money and convenience. Among the route of administration, the oral segment occupied the largest share as most of the medications available in the market are in the form of tablets or pills that can easily be administered by the patients.

Based on region, North America occupied the largest share in 2017 owing to the highest prevalence rate for thyroid disorders, large number of diagnosed patients as compared to other regions, and well-established healthcare infrastructure. However, Asia-Pacific is expected to grow at the highest CAGR of 4.4% during the study period, due to increase in number of thyroid disease awareness programs in the developing regions and availability of large number of undiagnosed thyroid gland disorder patients.

Key Findings Of The Thyroid Gland Disorder Treatment Market:

The Liothyronine segment is projected to grow at the highest rate among the drug type segment during the analysis period.
North America dominated global thyroid gland disorder treatment market in 2017, and is projected to continue its dominance in future.
China is expected to grow at the highest rate in Asia-Pacific during the forecast period.
Wholesaler/distributor is the largest contributor among the distribution channels segments in 2017.
The hypothyroidism segment generated the highest revenue, and is expected to continue its dominance in future.

The key players operating in the global thyroid gland disorder treatment market include AbbVie Inc., Pfizer Inc., Merck & Co., Inc., Lannett Company, Inc., Allergan plc, Mylan N.V., GlaxoSmithKline plc, Novartis AG, RLC LABS, Inc., and Abbott Laboratories. Other prominent players in the value chain include Takeda Pharmaceutical Company Limited, Aspen, Amgen Inc., Endo International plc, Acella Pharmaceuticals, LLC, and Gemini Laboratories, LLC.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll